Skip to main content

Advertisement

SpringerLink
Log in

Gastrointestinal Stromal Tumors: Case Series of 29 Patients Defining the Role of Imatinib Prior to Surgery

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to assess the role of neoadjuvant imatinib in redefining treatment for gastrointestinal stromal tumors (GISTs).

Methods

A total of 76 patients were reviewed. Among them, 29 patients who were administered neoadjuvant imatinib for borderline resectable and locally advanced GISTs followed by surgery were analyzed. Adjuvant imatinib was administered based on risk stratification.

Results

The median age of the neoadjuvant imatinib group was 51 years. The median duration of neoadjuvant imatinib administration was 8.5 months. The response rate with neoadjuvant imatinib was 79.3%. Five patients, initially considered to have locally unresectable lesions, ultimately underwent resection (three R0, two R2). Another three patients, who had M1 disease, underwent R2 resection (due to the presence of metastasis) with complete resection of the primary lesion. In 19 patients, who would have originally required extensive surgery, underwent conservative surgery (R0). In two patients, neoadjuvant imatinib did not influence the final procedure. The postoperative complication rate was 13.8%, and there were no postoperative deaths. There was one locoregional recurrence and two cases of distant metastasis. The 1-, 2-, and 3-year overall survivals were each 100%.

Conclusions

Neoadjuvant imatinib for locally advanced GISTs is a safe concept for downsizing, improving resectability, and aiding organ-preserving surgery. It also improves the chance of long-term survival. Surgery, however, remains the cornerstone of curative treatment of GISTs even after neoadjuvant imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hirota S, Isozki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  PubMed  CAS  Google Scholar 

  2. Nishida T, Hirota S (2000) Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 15:1293–1301

    PubMed  CAS  Google Scholar 

  3. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    PubMed  CAS  Google Scholar 

  4. Dematteo RP, Heinrich MC, El-Riffai WM et al (2002) Clinical management of gastrointestinal stromal tumors: before and after STI571. Hum Pathol 33:466–477

    Article  PubMed  CAS  Google Scholar 

  5. Arolfo S, Teggia PM, Nano M (2011) Gastrointestinal stromal tumors: thirty years experience of an institution. World J Gastroenterol 17:1836–1839

    Article  PubMed  Google Scholar 

  6. Frankel TL, Chang AE, Wong SL (2011) Surgical options for localized and advanced gastrointestinal stromal tumors. J Surg Oncol. doi:10.1002/jso.21892

  7. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:471–480

    Article  Google Scholar 

  8. Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib after resection of localised primary GIST: a randomized, double blind, placebo controlled trial. Lancet 373:1097–1104

    Article  PubMed  CAS  Google Scholar 

  9. National Comprehensive Cancer Network (2009) Soft tissue sarcoma. In: NCCN clinical practice guidelines in oncology. www.nccn.org. Accessed June 2011

  10. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–464

    Article  PubMed  Google Scholar 

  11. Lakshmi VA, Chacko RT, Kurian S (2010) Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital. Indian J Pathol Microbiol 53:628–633

    Article  PubMed  Google Scholar 

  12. Reid R, Bulusu R, Buckels J, et al. (2006) Guidelines for the management of gastrointestinal stromal tumors (GISTs). Novartis Oncology. http://www.novartisoncology.com. Accessed June 2011

  13. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  14. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213

    Article  PubMed  Google Scholar 

  15. Saied GM, Kensarah AM (2010) Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg 8:105–108

    Article  PubMed  Google Scholar 

  16. Raut CP, Posner M, Desai J et al (2006) Surgical management of adjuvant GIST after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  PubMed  CAS  Google Scholar 

  17. DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic GIST. Ann Surg 245:347–352

    Article  PubMed  Google Scholar 

  18. Blesius A, Cassier PA, Bertucci F et al (2011) Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11:72

    Article  PubMed  CAS  Google Scholar 

  19. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  PubMed  CAS  Google Scholar 

  20. Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following targeted therapy with imatinib in advanced/metastatic GIST. Ann Surg 245:341–346

    Article  PubMed  Google Scholar 

  21. Eisenberg BL, Harris J, Blanke CD et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib in for advanced primary and metastatic/recurrent operable GIST: early results of RTOG-0132/ACRIN 6664. J Surg Oncol 99:42–47

    Article  PubMed  CAS  Google Scholar 

  22. Elliott MA, Mesa RA, Tefferi A et al (2002) Adverse events after imatinib mesylate therapy. N Engl J Med 346:712–713

    Article  PubMed  Google Scholar 

  23. Blanke CD, Demetri GD, Von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 4:620–625

    Article  Google Scholar 

  24. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  25. Richter KK, Schmid C, Thompson-Fawcett M et al (2008) Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumors. Langenbecks Arch Surg 393:949–955

    Article  PubMed  Google Scholar 

  26. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred cases of GIST: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  PubMed  CAS  Google Scholar 

  27. DeMatteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size and location independently predicts recurrence after resection of primary GIST. Cancer 112:608–615

    Article  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gastrointestinal and HPB Surgical Oncology, Tata Memorial Hospital, Ernest Borges Marg, Parel, Mumbai, 400012, Maharashtra, India

    Shailesh V. Shrikhande, Sachin S. Marda, Kunal Suradkar, Guruprasad S. Shetty, Parul J. Shukla & Mahesh Goel

  2. Department of Radiology, Tata Memorial Hospital, Mumbai, India

    Supreeta Arya

  3. Department of Pathology, Tata Memorial Hospital, Mumbai, India

    Munita Bal

  4. Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Mumbai, India

    K. M. Mohandas

Authors
  1. Shailesh V. Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sachin S. Marda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kunal Suradkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Supreeta Arya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guruprasad S. Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Munita Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Parul J. Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mahesh Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K. M. Mohandas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shailesh V. Shrikhande.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shrikhande, S.V., Marda, S.S., Suradkar, K. et al. Gastrointestinal Stromal Tumors: Case Series of 29 Patients Defining the Role of Imatinib Prior to Surgery. World J Surg 36, 864–871 (2012). https://doi.org/10.1007/s00268-012-1440-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-012-1440-4

Keywords

Search

Navigation